Search results
Showing 46 to 60 of 99 results for insulin
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Discontinued Reference number: GID-TAG244
In development Reference number: GID-TA11104 Expected publication date: TBC
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
Discontinued Reference number: GID-TA10375
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
combinations (for example, glucagon‑like peptide‑1 [GLP‑1] mimetics and insulin combination therapy with meglitinides) are most...
Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)
In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008
NICE makes 4 types of recommendation that allow us to produce clear, directive, actionable guidance that is easy to understand and put into practice.
Dapagliflozin with insulin for treating type 1 diabetes (TA597)
In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
View recommendations for MPG2Show all sections
Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making
What are the barriers that women experience to achieving blood glucose targets?
regimen of blood glucose testing up to 7 times a day, and the need to adjust insulin dosage. A better understanding of the barriers in...
Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (HTG423)
Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.